American Society of Hematology

Fig. 10.

$Fig. 10. Follow-up of patients with AML with enhanced tryptase levels. / In patients with AML with elevated serum tryptase, enzyme levels were monitored during and after induction chemotherapy by serial measurements. In patients with continuous CR, serum tryptase levels remained in the normal range (A; M1, 29.8 ng/mL) By contrast, in patients with blast cell persistence or rapid regrowth of blast cells, tryptase levels often remained elevated or showed a recurrent increase. (B) This panel shows a patient (M0, 180 ng/mL) with blast cell persistence (refractory to induction chemotherapy) and persistently elevated serum tryptase. (C) This panel shows a patient with AML M2 (41.6 ng/mL) who entered CR after 2 induction cycles and relapsed during consolidation therapy.$

Follow-up of patients with AML with enhanced tryptase levels.

In patients with AML with elevated serum tryptase, enzyme levels were monitored during and after induction chemotherapy by serial measurements. In patients with continuous CR, serum tryptase levels remained in the normal range (A; M1, 29.8 ng/mL) By contrast, in patients with blast cell persistence or rapid regrowth of blast cells, tryptase levels often remained elevated or showed a recurrent increase. (B) This panel shows a patient (M0, 180 ng/mL) with blast cell persistence (refractory to induction chemotherapy) and persistently elevated serum tryptase. (C) This panel shows a patient with AML M2 (41.6 ng/mL) who entered CR after 2 induction cycles and relapsed during consolidation therapy.

This Feature Is Available To Subscribers Only